Winner profile: custom antibody or alternative affinity reagent supplier

We recently announced the winners of the 2017 CiteAb Antibody Awards, and today we feature the winner profile here on our blog for the category of ‘Custom antibody or alternative affinity reagent supplier 2017’.

The winners of this category for 2017 are Bio-Rad, headquartered in California, USA, and trading internationally.

This category recognises a supplier of custom antibodies or alternative affinity reagents that consistently offers its customers an excellent service and fills a niche in the market. Bio-Rad was runner up in the category in our 2016 awards, and has mad significant efforts to grow its strength in custom reagents since then, making it a very worth 2017 winner.

Whether they need entirely new antibodies, are outsourcing the production of antibodies from hybridomas or need to scale-up numbers of an existing product, Bio-Rad’s antibody experts aim to support the company’s customers with a range of custom services and a wealth of experience.

A spokesperson from the company said: “We consider it an honour to be listed as the best in custom antibody service. More importantly, we are particularly delighted to have been nominated for this award by our customers who stated that they were especially impressed with the service we provide.

“We are constantly expanding our services to satisfy the growing needs of scientists as they aim to make significant advances in understanding biology and addressing unmet clinical needs. In 2017, we will continue to partner with scientists to achieve these goals.”

Andrew Chalmers, Founder of CiteAb, said: “Congratulations to Bio-Rad. The company has developed a clear niche in in-vitro recombinant antibody technology and also has an established focus on providing excellent customer service. These two factors, hand-in-hand, make Bio-Rad a worthy winner.”

You can learn more about Bio-Rad’s custom antibody production service here

 

Join thousands of people who already enjoy the CiteAb newsletter

To keep up to date with the latest developments to our search engine, news from our life science market data analysis and improvements to our citation provision.